Acquired DNA mutations in adults with myeloproliferative disorders receiving hydroxyurea therapy.

被引：0
|
作者：
Hanft, VN
Fruchtman, S
Heumayer, S
Weinberg, JB
Howard, TA
Ware, RE
机构：
[1] DUKE UNIV,MED CTR,DURHAM,NC
[2] DURHAM VA HOSP,DURHAM,NC
[3] MT SINAI HOSP,NEW YORK,NY 10029
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1542 / 1542
页数：1
相关论文
共 41 条
  • [1] Acquired DNA mutations and the leukemogenic potential of hydroxyurea therapy.
    Ware, RE
    Hanft, VN
    Pickens, CV
    Rosse, WF
    Fruchtman, SR
    Howard, TA
    BLOOD, 1998, 92 (10) : 424A - 424A
  • [2] Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders
    Ravandi-Kashani, F
    Cortes, J
    Cohen, P
    Talpaz, M
    O'Brien, S
    Markowitz, A
    Kantarjian, H
    LEUKEMIA & LYMPHOMA, 1999, 35 (1-2) : 109 - 118
  • [3] Acquired DNA mutations associated with in vivo hydroxyurea exposure
    Hanft, VN
    Fruchtman, SR
    Pickens, CV
    Rosse, WF
    Howard, TA
    Ware, RE
    BLOOD, 2000, 95 (11) : 3589 - 3593
  • [4] Interferon-alpha and hydroxyurea in the therapy of hyperthrombocytosis, associated with myeloproliferative disorders
    Khoroshko, ND
    Tsvetaeva, NV
    Turkina, AG
    Zhuravlev, VS
    Lukina, EA
    Semenova, EA
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 313 - 313
  • [5] Cutaneous ulcers associated with hydroxyurea (HU) therapy in myeloproliferative disorders.
    Ravandi-Kashani, F
    Cortes, J
    Cohen, P
    Talpaz, M
    O'Brien, S
    Thomas, D
    Markowitz, A
    Kantarjian, HM
    BLOOD, 1998, 92 (10) : 248B - 248B
  • [6] Acquired von Willebrand syndrome (AVWS) in chronic myeloproliferative disorders (MPD): Clinical and laboratory features, and response to therapy.
    Elliott, MA
    Plumhoff, EA
    Nichols, WL
    Heit, JA
    Fass, DN
    Kumar, SK
    Tefferi, A
    BLOOD, 2003, 102 (11) : 311A - 311A
  • [7] Safe and effective use of combination therapy with anagrelide and hydroxyurea in patients with chronic myeloproliferative disorders
    Adu, R. Kesse
    Wiles, N. M.
    Francis, Y.
    McMullin, M. F.
    Reilly, J. T.
    Green, A. R.
    Beer, P.
    Radia, D. H.
    Harrison, C. N.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 64 - 65
  • [8] Acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination with endocrine therapy.
    Goetz, Matthew P.
    Paige Hamilton, Erika
    Campone, Mario
    Hurvitz, Sara A.
    Cortes, Javier
    Johnston, Stephen R. D.
    Maria Jerusalem, Guy Heinrich
    Graham, Hillary
    Wang, Hong
    Litchfield, Lacey
    Malyvanh Jansen, Valerie
    Martin, Miguel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Myeloproliferative disorders are associated with an increase in levels of prothrombotic and inflammatory markers despite cytoreductive therapy.
    Cheung, Betty Y. Y.
    Hunt, Beverley J.
    Parmar, Kiran
    Daniel, Yvonne
    Radia, Deepti
    Harrison, Claire N.
    BLOOD, 2006, 108 (11) : 1035A - 1036A
  • [10] Acquired factor VIII inhibitor in a patient with CML receiving chronic interferon-α therapy.
    English, KE
    Brien, WF
    Howson-Jan, K
    Kovacs, MJ
    BLOOD, 1999, 94 (10) : 273B - 273B
12345